Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas.

Proceedings of the National Academy of Sciences of the United States of America - 9 Apr 2013

Sievert Angela J, Lang Shih-Shan, Boucher Katie L, Madsen Peter J, Slaunwhite Erin, Choudhari Namrata, Kellet Meghan, Storm Phillip B, Resnick Adam C

Abstract excerpt

Astrocytomas are the most common type of brain tumors in children. Activated BRAF protein kinase mutations are characteristic of pediatric astrocytomas with KIAA1549-BRAF fusion genes typifying low-grade astrocytomas and (V600E)BRAF alterations characterizing distinct or higher-grade tumors. Recently, BRAF-targeted therapies, such as vemurafenib, have shown great promise in treating V600E-dependent melanomas....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Astrocytoma
Share to Indoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoplasm Transplantation

Share to NIH 3T3 Cells

Share to Oncogene Proteins, Fusion

Share to Protein Interaction Mapping

Share to Sulfonamides

Share to Vemurafenib

Source

Open in PubMed Open full text

Identifiers

PMID: 23533272
DOI: 10.1073/pnas.1219232110
PMCID: PMC3625308

Genes

BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas.PMID 23533272Read ↗

CRAF gene fusions in pediatric low-grade gliomas define a distinct drug response based on dimerization profilesSemantic proximity Read ↗

BRAF Dimerization: An Underlying Resistance Mechanism in Low-Grade Pediatric Gliomas.Semantic proximity Read ↗

Novel BRAF fusions in pediatric histiocytic neoplasms define distinct therapeutic responsiveness to RAF paradox breakersSemantic proximity Read ↗

BRAF fusions in pediatric histiocytic neoplasms define distinct therapeutic responsiveness to RAF paradox breakersSemantic proximity Read ↗

BRAF fusions in pediatric histiocytic neoplasms define distinct therapeutic responsiveness to RAF paradox breakers.Semantic proximity Read ↗

Targeting Oncogenic BRAF: Past, Present, and FutureSemantic proximity Read ↗

Current Understanding of BRAF Alterations in Diagnosis, Prognosis, and Therapeutic Targeting in Pediatric Low-Grade GliomasSemantic proximity Read ↗

Molecular Heterogeneity in BRAF-Mutant Gliomas: Diagnostic, Prognostic, and Therapeutic ImplicationsSemantic proximity Read ↗

Targeted therapy for BRAFV600E malignant astrocytoma.Semantic proximity Read ↗

Acquired resistance to BRAF inhibition in BRAFV600E mutant gliomas.Semantic proximity Read ↗

BRAF - a tumour-agnostic drug target with lineage-specific dependencies.Semantic proximity Read ↗

Resistance mechanisms in BRAFV600E paediatric high-grade glioma and current therapeutic approachesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.